This intermittent adaptive therapy protocol (Figure 1C) used MTD of single-agent abiraterone until the tumor burden (measured by prostate-specific antigen (PSA) in the blood) fell below 50% of its initial level. This evidence concerns the gene KLK3 and neoplasm.